American College of Cardiology 2020 Scientific Session (ACC.20)/World Congress of Cardiology (WCC)

Chicago, Illinois 28 March 2020 - 30 March 2020

Ticagrelor benefits in TWILIGHT hold up in diabetes

23 Apr 2020 by

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

Ticagrelor benefits in TWILIGHT hold up in diabetes

23 Apr 2020

Ticagrelor monotherapy outshines DAPT after complex PCI

23 Apr 2020 by

Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.

Ticagrelor monotherapy outshines DAPT after complex PCI

23 Apr 2020

TICO backs ticagrelor alone in ACS post-PCI

23 Apr 2020 by

Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.

TICO backs ticagrelor alone in ACS post-PCI

23 Apr 2020

Apixaban on par with dalteparin in reducing VTE recurrence in cancer

22 Apr 2020 by

Patients with cancer who develop venous thromboembolism (VTE) could reduce their risk of VTE recurrence with the direct oral anticoagulant (DOAC) apixaban, which demonstrated noninferiority to subcutaneous dalteparin in the Caravaggio* trial.

Apixaban on par with dalteparin in reducing VTE recurrence in cancer

22 Apr 2020

Rivaroxaban prevents VTE after lower limb surgery

18 Apr 2020 by

Rivaroxaban reduced venous thromboembolism (VTE) risk without increasing bleeding compared with enoxaparin in patients who underwent lower limb nonmajor orthopaedic surgery, the PRONOMOS* trial showed.

Rivaroxaban prevents VTE after lower limb surgery

18 Apr 2020

TAVR for low-risk patients with bicuspid valves?

15 Apr 2020 by

Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic stenosis who are at low surgical risk appears to be safe with low rates of death or disabling stroke at 30 days, according to a study presented at the ACC.20/WCC Virtual Meeting.

TAVR for low-risk patients with bicuspid valves?

15 Apr 2020

Adding an old gout drug to standard therapy cost-effective post-MI

13 Apr 2020 by

A gout drug that’s been around for years reduced the risk of ischaemic cardiovascular (CV) events when given at a low dose in patients who had myocardial infarction (MI) and was cost-effective, an analysis of the COLCOT* trial has shown.

Adding an old gout drug to standard therapy cost-effective post-MI

13 Apr 2020

Adverse pregnancy outcomes: A signal of heart failure?

10 Apr 2020 by

Adverse pregnancy outcomes (APOs) could predict a woman’s risk of heart failure (HF) up to 30 years later, according to findings from the CARDIA* study presented at ACC.20.

Adverse pregnancy outcomes: A signal of heart failure?

10 Apr 2020

Radial artery grafting confers survival benefit over saphenous vein in CABG

09 Apr 2020 by

For patients undergoing CABG*, using a radial artery graft to create the second bypass conduit led to better 10-year survival and cardiovascular outcomes than using a saphenous vein grafting, according to the RADIAL** meta-analysis presented at the recent ACC.20/WCC Virtual Meeting.

Radial artery grafting confers survival benefit over saphenous vein in CABG

09 Apr 2020

Alirocumab shows LDL-C-lowering potential in homozygous FH

08 Apr 2020 by

Treatment with the PCSK9* inhibitor alirocumab led to clinically meaningful reductions in low-density lipoprotein cholesterol (LDL-C) among adults with homozygous familial hypercholesterolaemia (HoFH), according to data from the ODYSSEY-HoFH** trial presented at the ACC.20/WCC Virtual meeting.

Alirocumab shows LDL-C-lowering potential in homozygous FH

08 Apr 2020